Gsk (GSK) Tax Provisions (2009 - 2026)

Gsk (GSK) has 18 years of Tax Provisions data on file, last reported at -$142.3 million in Q3 2026.

• For the quarter ending Q3 2026, Tax Provisions changed N/A year-over-year to -$142.3 million; the trailing twelve-month figure through Sep 2026 stood at -$1.8 billion (changed N/A YoY), and the FY2025 full-year result was -$1.5 billion, down 119.99% from the prior year.
• Tax Provisions was -$142.3 million for Q3 2026 at Gsk, down from $267.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $267.0 million in Q2 2026 to a low of -$1.5 billion in Q4 2025.
• A 5-year average of -$411.7 million and a median of -$335.5 million in 2023 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions tumbled 32502.13% in 2025 and surged 183.05% in 2026, its largest moves.
• Gsk's Tax Provisions stood at -$829.3 million in 2022, then retreated by 13.15% to -$938.3 million in 2023, then increased by 28.05% to -$675.1 million in 2024, then slumped by 119.09% to -$1.5 billion in 2025, then soared by 90.38% to -$142.3 million in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were -$142.3 million in Q3 2026, $267.0 million in Q2 2026, and -$411.2 million in Q1 2026.